Categories: Product News

First contract signed for new CANTAB Recruit web-based patient recruitment product

New Delhi, September 29, 2016: The neuroscience company Cambridge Cognition Holdings PLC (Cambridge, UK – LSE: COG), which develops and markets near patient technologies to facilitate early intervention and development of treatments for neurological disorders, today announced that it has secured the first contract for CANTAB Recruit with one of the world’s largest biotechnology companies.

This recently launched online patient recruitment product accelerates the identification of qualified clinical trial participants in high-need neurological indications.

Patient recruitment alone amounts to one third of total trial costs1with 80% of development programmes being delayed due to unfulfilled enrolment numbers2. By remotely pre-screening subjects using proprietary CANTAB® cognitive assessment, Recruit is expected to significantly reduce the cost and time of recruitment for drug development companies.

This first partnership will use CANTAB Recruit to support patient enrolment in a late-phase Alzheimer’s disease trial, helping to accelerate the development of a new drug treatment.

The commercialisation of CANTAB Recruit represents a significant milestone for Cambridge Cognition in the Company’s provision of end-to-end neurocognitive services for corporate partners to accelerate the development of optimal treatments from proof of concept studies to post-marketing.

Steven Powell, PhD, Chief Executive Officer, Cambridge Cognition: “As pharmaceutical development moves towards preventative medicine, our customers and partners face a growing challenge to find suitable subjects with neurological disease in the early stages of cognitive decline. CANTAB Recruit will enrich recruitment practices by reducing on-site screen failure rates, saving sponsors substantial time and cost. With the number of drug development programmes in Alzheimer’s disease increasing, we forecast that CANTAB Recruit will lead to significant opportunities beyond this initial contract for the Company and its partners.”

Corporate Comm India(CCI Newswire)

The Pharma Times News Bureau

Recent Posts

10 PCOS Warning Signs That Need Your Attention

By Dr. Sandhya Rani, Sr. Consultant - Obstetrics & Gynaecology, Aster Women & Children Hospital,…

14 hours ago

Sri Ramakrishna Hospital Drives Awareness of Rheumatic Disease, Emphasizing the Significance of Early Diagnosis and Lifestyle Changes

Coimbatore, December 28, 2024: Sri Ramakrishna Hospital took a proactive approach to combat the rising…

14 hours ago

Arjun Deshpande Honors Shri Ratan Tata’s 87th Birthday with a Lifesaving Initiative.

The 22-Year-Old Founder of Generic Aadhaar Distributes Free Cancer Medicines to 87 Patients, Advancing Shri…

14 hours ago

Venus Remedies partners with NSDC to pioneer workforce development through skill certification

Initiative aimed at enhancing workforce skills and competency in line with industry standards so as…

1 day ago

80-Year-Old Diabetic Patient’s second leg Saved at Apex Group of Hospitals, Borivali

Previously, the patient underwent an above-knee amputation in the USA due to similar complications in the…

1 day ago

Miraculous Recovery: 23-weeker Micro-Preemie Thrives After 100 Days in NICU at Motherhood Hospitals, Kharghar

New Delhi, December 27, 2024: A team of expert obstetricians & neonatologists at Motherhood Hospitals,…

1 day ago